Patents by Inventor Michael Molhoj

Michael Molhoj has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317879
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: June 4, 2024
    Publication date: September 26, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Patent number: 12030952
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: July 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20240141044
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 6, 2023
    Publication date: May 2, 2024
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Patent number: 11958912
    Abstract: Herein is reported a method for determining the binding interaction with a multimeric antigen of an antibody of the human IgG1 subclass that has at least two binding sites specifically binding to the antigen comprising the steps of 1) determining the binding affinity of the antibody for the multimeric antigen, and 2) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis under conditions and for a time sufficient to cleave the antibody into Fabs and Fc-region, and determining the binding affinity of the Fabs of the antibody for the multimeric, whereby the binding affinity of the antibody to the multimeric antigen to be affinity-driven if the binding affinity determined in both steps are comparable and to be avidity-driven if the binding affinity determined in both steps are different.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: April 16, 2024
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joerg Moelleken, Michael Molhoj, Christian Gassner, Manuel Endesfelder, Joerg-Thomas Regula
  • Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Publication number: 20230374119
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: June 22, 2023
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine lmhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph UlImer, Barbara Weiser
  • Publication number: 20230365702
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: April 10, 2023
    Publication date: November 16, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11787868
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: October 17, 2023
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Publication number: 20230287118
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: October 13, 2022
    Publication date: September 14, 2023
    Inventors: Oliver AST, Marina Bacac, Sabine Imhof-Jung, Christiane Neumann, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Publication number: 20230265177
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 29, 2022
    Publication date: August 24, 2023
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Patent number: 11732036
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: August 22, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
  • Patent number: 11603411
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11572404
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 7, 2023
    Assignee: Hoffman-La Rocher Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20220403027
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: April 1, 2022
    Publication date: December 22, 2022
    Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane NEUMANN, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
  • Publication number: 20220363771
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: January 27, 2022
    Publication date: November 17, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Thomas REGULA, Wolfgang SCHAEFER, Michael MOLHOJ, Sabine IMHOF-JUNG, Christian KLEIN
  • Patent number: 11486882
    Abstract: Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: November 1, 2022
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Michael Molhoj, Maximiliane Koenig, Vincent Larraillet, Katja Montan, Bianca Gruenwalder
  • Publication number: 20220306761
    Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 29, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
  • Publication number: 20220204616
    Abstract: Herein is reported an antibody that specifically hinds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.
    Type: Application
    Filed: January 19, 2022
    Publication date: June 30, 2022
    Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere
  • Publication number: 20220144963
    Abstract: Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.
    Type: Application
    Filed: December 22, 2020
    Publication date: May 12, 2022
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 11286300
    Abstract: Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Guy Georges, Alexander Haas, Hubert Kettenberger, Ekkehard Moessner, Tilman Schlothauer, Michael Molhoj, Laurent Lariviere